IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 4144 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3247    
    Printed70    
    Emailed0    
    PDF Downloaded240    
    Comments [Add]    

Recommend this journal

 

 REVIEW ARTICLE
Year : 2015  |  Volume : 47  |  Issue : 6  |  Page : 585-593

Investigation of comparative effectiveness research in Asia, Europe, and North America


1 Department of Biopharmaceutical Sciences, Shenandoah University, Winchester, VA, USA
2 The University of Toledo Medical Center, Toledo, OH, USA
3 Department of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, WV, USA
4 Department of Pharmaceutical Policy and Outcomes Research, Sungkyunkwan University, Seoul, South Korea
5 Department of Clinical Pharmacy, UCSI University, Kuala Lumpur, Malaysia
6 Department of Pharmaceutical, Social and Administrative Sciences, Samford University, Birmingham, AL, USA

Correspondence Address:
Dr. Jongwha Chang
Department of Pharmaceutical, Social and Administrative Sciences, Samford University, Birmingham, AL
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.169592

Rights and Permissions

Comparative effectiveness research (CER) is an important branch of pharmacoeconomics that systematically studies and evaluates the cost-effectiveness of medical interventions. CER plays instrumental roles in guiding government public health policy programs and insurance. Countries throughout the world use different methods of CER to help make medical decisions based on providing optimal therapy at a reduced cost. Expenses to the healthcare system continue to rise, and CER is one-way in which expenses could be curbed in the future by applying cost-effectiveness evidence to clinical decisions. China, India, South Korea, and the United Kingdom are of essential focus because these country's economies and health care expenses continue to expand. The structures and use of CER are diverse throughout these countries, and each is of prime importance. By conducting this thorough comparison of CER in different nations, strategies and organizational setups from different countries can be applied to help guide public health and medical decision-making in order to continue to expand the establishment and role of CER programs. The patient-centered medical home has been created to help reduce costs in the primary care sector and to help improve the effectiveness of therapy. Barriers to CER are also important as many stakeholders need to be able to work together to provide the best CER evidence. The advancement of CER in multiple countries throughout the world provides a possible way of reducing costs to the healthcare system in an age of expanding expenses.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow